DYAI DYAI
Company Profile ↓Company Overview
DYAI (DYAI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 19.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.09M (-11.6% YoY); net profit $-7.36M.
- Trailing 12 Months Year-on-year growth — revenue -11.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.20% |
| 1 Year: | -11.59% |
Stock Price Performance
| 1 Year: | -4.01% |
| 6 Months: | +14.06% |
| 3 Months: | +25.91% |
| 1 Month: | -8.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross7d ago
- RSI (14)43.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 34.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 184.33K | 161.29K | 262.96K | 402.53K | 390.87K | 454.51K | 315.37K | 524.27K | 416.36K | 460.52M | 937.09K | 692.93K | 648.43K | 658.55K | 879.60K | 978.05K | 837.16K | 397.06K | 334.62K | 385.90K | 1.96M | 393.57K | 966.63K | 1.16M | 1.11M |
| Operating Income | -2.23M | -1.82M | -1.78M | -2.44M | -2.96M | -1.94M | -2.38M | -2.80M | -2.58M | -3.32B | -3.87M | -3.32M | -2.74M | -3.32M | -1.86M | -2.05M | -2.29M | -1.72M | -2.13M | -2.04M | -202.61K | -2.00M | -1.73M | -1.93M | -1.90M |
| Net Income | -2.04M | -1.60M | -1.54M | -2.18M | -2.70M | -1.70M | -2.21M | -2.65M | -2.50M | -3.29M | -3.85M | -1.72M | -2.49M | -3.29M | -1.81M | -956.44K | -2.15M | -1.61M | -2.01M | -2.05M | -203.46K | -2.03M | -1.79M | -1.98M | -1.95M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.07 | -0.01 | -0.07 | -0.06 | -0.06 | -0.05 |
| R&D Expense | 576.88K | 601.20K | 476.63K | 692.37K | 818.24K | 841.34K | 755.45K | 1.12M | 986.05K | 1.81B | 2.21M | 1.90M | 1.34M | 1.83M | 743.59K | 810.57K | 917.55K | 716.35K | 522.72K | 515.63K | 460.24K | 494.98K | 629.38K | 571.87K | 476.07K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 758.42K | 1.30M | 1.68M | 1.60M | 2.40M | 2.93M | 2.90M | 3.50M | 3.09M |
| Operating Income | -7.13M | -7.59M | -9.28M | -10.03M | -14.73M | -10.17M | -8.23M | -5.90M | -7.19M |
| Net Income | -2.14M | -5.69M | -8.31M | -9.33M | -13.07M | -9.74M | -6.80M | -5.81M | -7.36M |
| Diluted EPS | - | - | - | - | - | - | - | -0.20 | -0.23 |
| R&D Expense | 1.77M | 2.10M | 3.09M | 3.87M | 8.39M | 4.50M | 3.30M | 2.04M | 2.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.74M | 43.30M | 37.45M | 30.07M | 21.30M | 13.71M | 8.22M | 9.93M | 9.95M |
| Total Equity | 57.69M | 49.98M | 42.45M | 35.86M | 28.45M | 18.39M | 11.09M | 5.88M | 2.47M | 1.23M |
| Cash & Equivalents | - | 5.79M | 2.39M | 4.82M | 20.64M | 15.75M | 5.79M | 6.52M | 6.51M | 4.62M |
| Total Liabilities | - | - | - | - | 1.63M | 2.91M | 2.63M | 2.34M | 7.46M | 8.71M |
| Current Liabilities | - | 768.89K | 849.64K | 1.59M | 1.63M | 2.56M | 2.45M | 2.25M | 2.45M | 3.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.69M | -4.41M | -5.78M | -6.57M | -11.28M | -8.08M | -6.73M | -3.97M | -5.70M |
| Investing Cash Flow | -812.08K | 3.33M | 7.71M | 22.12M | 5.22M | -2.37M | 7.45M | -1.88M | 82.08K |
| Financing Cash Flow | -6.22M | -2.30M | 550.19K | 255.47K | 1.23M | 543.59K | 0 | 5.85M | 4.96M |
| Share Buybacks | 6.22M | 2.30M | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -939.7% | -586.1% | -552.2% | -625.9% | -612.7% | -346.9% | -283.9% | -168.8% | -232.8% |
| Net Margin % | -281.6% | -439.4% | -494.2% | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -238.3% |
| ROE % | -4.3% | -13.4% | -23.2% | -32.8% | -71.1% | -87.8% | -115.6% | -235.2% | -597.6% |
| ROCE % | -14.3% | -17.9% | -25.9% | -35.2% | -78.6% | -90.2% | -137.9% | -78.9% | -114.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DYAI
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategyJUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Internation…
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production …
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand platform adoption, and create future co…
Dyadic Announces Continued Listing on the Nasdaq Capital Market
JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life scie…
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platformJUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolu…
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant FundingJUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyad…
DYAI — Frequently Asked Questions
What is the current share price of DYAI?
As of 2026-08-05 17:25 PDT, DYAI trades at $0.97 on NASDAQ/NYSE. Its 52-week range is $0.68 to $1.47.
What is the P/E ratio of DYAI?
DYAI trades at a trailing price-to-earnings (P/E) ratio of -4.22.
Is DYAI a good stock to buy?
This page provides a data-driven analysis of DYAI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.